Company Profile
Blue Earth Diagnostics
Company Overview
Blue Earth Diagnostics is a molecular imaging diagnostics company based in Burlington, MA focused on the development and commercialization of novel PET imaging agents to inform clinical management and guide care for cancer patients.
Formed in 2014, Blue Earth Diagnostics is led by recognized experts in the clinical development and commercialization of innovative nuclear medicine products. The company’s first approved and commercially available product is Axumin™ (fluciclovine F 18), a novel molecular imaging agent approved in the United States and the European Union for use in PET imaging to detect and localize prostate cancer in men experiencing suspected biochemical recurrence. In 2018, BED submitted FDA filing for Axumin’s approval for Glioma imaging and acquired a radio-hybrid prostate specific membrane antigen (rhPSMA) for development in the diagnostic and therapeutic settings.